Literature DB >> 28670070

Two cancers in one: breast carcinoma with underlying melanoma.

Nicholas A Douville1, Elizabeth A Sakach1, Elizabeth A Wiewiorowski1, William Herlihy1, John E Pippen1.   

Abstract

A 61-year-old woman presented with a diagnosis of metastatic invasive lobular carcinoma of the right breast, and after treatment it had regressed or was stable except for a scalp nodule. When biopsied, the outer edges of the scalp lesion had findings consistent with breast carcinoma; however, the bulk of the tumor's pathology was consistent with melanoma. It appeared that most of the tumor was a highly vascularized melanoma with lobular breast carcinoma noted at its edges.

Entities:  

Year:  2017        PMID: 28670070      PMCID: PMC5468027          DOI: 10.1080/08998280.2017.11929630

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  11 in total

1.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.

Authors:  C J van Asperen; R M Brohet; E J Meijers-Heijboer; N Hoogerbrugge; S Verhoef; H F A Vasen; M G E M Ausems; F H Menko; E B Gomez Garcia; J G M Klijn; F B L Hogervorst; J C van Houwelingen; L J van't Veer; M A Rookus; F E van Leeuwen
Journal:  J Med Genet       Date:  2005-09       Impact factor: 6.318

2.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

3.  High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.

Authors:  A Borg; T Sandberg; K Nilsson; O Johannsson; M Klinker; A Måsbäck; J Westerdahl; H Olsson; C Ingvar
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

4.  Increased risk of second cancers following breast cancer: role of the initial treatment.

Authors:  C Rubino; F de Vathaire; I Diallo; A Shamsaldin; M G Lê
Journal:  Breast Cancer Res Treat       Date:  2000-06       Impact factor: 4.872

5.  Genetic alterations in quadruple malignancies of a patient with multiple sclerosis: their role in malignancy development and response to therapy.

Authors:  Zorica Milosevic; Nikola Tanic; Jasna Bankovic; Tijana Stankovic; Marko Buta; Dragana Lavrnic; Zorka Milovanovic; Gordana Pupic; Sonja Stojkovic; Vedrana Milinkovic; Yasuhiro Ito; Radan Dzodic
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 6.  Multiple primary malignant neoplasms: case report and a comprehensive review of the literature.

Authors:  Carlo Greg N Demandante; Dean A Troyer; Toni P Miles
Journal:  Am J Clin Oncol       Date:  2003-02       Impact factor: 2.339

7.  Increased risk of breast cancer in relatives of malignant melanoma patients from families with strong cancer familial aggregation.

Authors:  T Debniak; B Górski; C Cybulski; A Jakubowska; G Kurzawski; J Kładny; E Załuga; J Fiedorowicz; B Debniak; J Lubiński
Journal:  Eur J Cancer Prev       Date:  2003-06       Impact factor: 2.497

8.  Risk of second primary malignancies among 1537 melanoma patients and risk of second primary melanoma among 52 354 cancer patients in Northern Italy.

Authors:  S Caini; D Radice; G Tosti; G Spadola; E Cocorocchio; P F Ferrucci; A Testori; E Pennacchioli; M C Fargnoli; D Palli; B Bazolli; E Botteri; S Gandini
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-03-18       Impact factor: 6.166

9.  Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.

Authors:  Nicholas Hearle; Bertil E Damato; Jane Humphreys; Julie Wixey; Helen Green; Joanne Stone; Douglas F Easton; Richard S Houlston
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-02       Impact factor: 4.799

10.  BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.

Authors:  Christian Monnerat; Agnès Chompret; Caroline Kannengiesser; Marie-Françoise Avril; Nicolas Janin; Alain Spatz; Jean-Marc Guinebretière; Catalin Marian; Michel Barrois; Françoise Boitier; Gilbert M Lenoir; Brigitte Bressac-de Paillerets
Journal:  Fam Cancer       Date:  2007-07-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.